Testing a stem cell treatment for liver cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a treatment made from stem cells to see if it is safe and can help reduce scarring and improve liver function in people with liver cirrhosis. It focuses on patients with moderate liver disease (Child-Pugh Class B).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with liver cirrhosis by a doctor and imaging tests.
- Your liver disease is at a moderate stage (Child-Pugh Class B).
- You are currently stable and do not have serious complications like active bleeding, severe infection, or severe kidney problems.
- You have not taken any experimental drugs for liver cirrhosis in the last 6 months.
- You are willing to follow the study plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of stem cell therapy is safe for people with liver cirrhosis caused by alcohol, hepatitis B, or hepatitis C. It may help if your liver disease is controlled and you have moderate to severe cirrhosis.
This trial tests whether using remote monitoring (checking your health from home) can help manage liver cirrhosis. It aims to make care easier and catch problems early without extra hospital visits.
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
This trial tests a new treatment made from stem cells (called a secretome) given through an IV to see if it is safe and helpful for people with epilepsy that does not improve with standard medicines. It is for adults ages 18 to 60 whose seizures are not controlled by at least two anti-seizure drugs.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial tests whether giving a combination of two medicines (GCSF and Darbepoetin) one time or multiple times can help people with early-stage liver cirrhosis who have started to develop complications. The goal is to see if this treatment can improve liver function and delay the need for a transplant.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.